ArticleRomanian journal of ophthalmology
Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment.
Article in Romanian journal of ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical treatments remain the primary therapeutic strategy for glaucoma, with the primary objective of reducing intraocular pressure (IOP), the only modifiable risk factor for the disease. While these medications are effective in lowering IOP, they are also associated with a variety of potential adverse effects. This study aims to compare the effects of various topical antiglaucoma medications on the ocular surface in patients with open-angle glaucoma or intraocular hypertension. Patients were classified based on their treatment type and assessed using the Schirmer test, tear break-up time (TBUT), and fluorescein staining. The monitoring period spanned from February 2019 to September 2024. Preliminary results suggested that the daily number of drops administered may have a more significant impact on outcomes than the presence or absence of preservatives in the eye drops.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.